BIO (STOCKS)
Bio-Rad Laboratories, Inc.Class A
$288.170000
+8.920000 (+3.19%)
Prev close: $279.250000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Medical Specialties
- CEO
- Norman D. Schwartz
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $7,780.80M
- Employees
- 7,700
- P/E (TTM)
- 10.03
- P/B (TTM)
- 1.01
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
4
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$2.51 | $2.73 | -0.2175 | -7.97% |
|
Sep 2025 (Q3)
|
$2.26 | $1.95 | +0.3074 | +15.74% |
|
Jun 2025 (Q2)
|
$2.61 | $1.75 | +0.8592 | +49.07% |
|
Mar 2025 (Q1)
|
$2.54 | $1.83 | +0.7122 | +38.96% |
Financial Statements
| Revenues | $2.58B |
| Benefits Costs and Expenses | $1.59B |
| Cost Of Revenue | $1.24B |
| Costs And Expenses | $1.59B |
| Gross Profit | $1.34B |
| Operating Expenses | $1.29B |
| Selling, General, and Administrative Expenses | $844.30M |
| Research and Development | $275.60M |
| Other Operating Expenses | $172.80M |
| Operating Income/Loss | $47.20M |
| Income/Loss From Continuing Operations After Tax | $759.90M |
| Income/Loss From Continuing Operations Before Tax | $995.50M |
| Income Tax Expense/Benefit | $235.60M |
| Income Tax Expense/Benefit, Current | $63.00M |
| Income Tax Expense/Benefit, Deferred | $170.50M |
| Interest Expense, Operating | $49.00M |
| Net Income/Loss | $759.90M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $759.90M |
| Net Income/Loss Available To Common Stockholders, Basic | $759.90M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $1.40M |
| Basic Earnings Per Share | $27.87 |
| Diluted Earnings Per Share | $27.85 |
| Basic Average Shares | 27,263,000 |
| Diluted Average Shares | 27,281,000 |
| Assets | $10.58B |
| Current Assets | $2.91B |
| Inventory | $740.70M |
| Prepaid Expenses | $136.50M |
| Other Current Assets | $2.03B |
| Noncurrent Assets | $7.67B |
| Fixed Assets | $539.90M |
| Intangible Assets | $174.30M |
| Other Non-current Assets | $6.96B |
| Liabilities | $3.12B |
| Current Liabilities | $517.00M |
| Accounts Payable | $129.00M |
| Wages | $172.30M |
| Other Current Liabilities | $215.70M |
| Noncurrent Liabilities | $2.61B |
| Long-term Debt | $1.20B |
| Other Non-current Liabilities | $1.40B |
| Equity | $7.45B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $7.45B |
| Liabilities And Equity | $10.58B |
| Net Cash Flow From Operating Activities | $532.20M |
| Net Cash Flow From Operating Activities, Continuing | $532.20M |
| Net Cash Flow From Investing Activities | -$189.70M |
| Net Cash Flow From Investing Activities, Continuing | -$189.70M |
| Net Cash Flow From Financing Activities | -$283.20M |
| Net Cash Flow From Financing Activities, Continuing | -$283.20M |
| Net Cash Flow | $59.30M |
| Net Cash Flow, Continuing | $59.30M |
| Comprehensive Income/Loss | $1.11B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $1.11B |
| Other Comprehensive Income/Loss | $349.10M |
| Other Comprehensive Income/Loss Attributable To Parent | $349.10M |